Laura B. Pritzker

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility.

Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility.

Journal: Cancers

Published: July 23, 2025

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

Journal: Breast cancer research : BCR

Published: March 23, 2025

Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.

Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.

Journal: JNCI cancer spectrum

Published: August 24, 2023

RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells.

RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells.

Journal: Scientific reports

Published: April 09, 2022

The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs.

The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs.

Journal: Scientific reports

Published: December 29, 2019

RNA disruption indicates CHOP therapy efficacy in canine lymphoma.

RNA disruption indicates CHOP therapy efficacy in canine lymphoma.

Journal: BMC veterinary research

Published: April 26, 2019

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Journal: Journal of the National Cancer Institute

Published: February 02, 2016

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.

Journal: BMC cancer

Published: November 29, 2015

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.

Journal: Journal of the National Cancer Institute. Monographs

Published: June 12, 2015

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

Journal: Breast cancer research and treatment

Published: March 31, 2015

Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.

Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.

Journal: Endocrine-related cancer

Published: May 09, 2014

Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".

Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".

Journal: Breast cancer research and treatment

Published: January 11, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026